Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Duff, K. et al., Increased amyloid-β 42(43) in brains of mice expressing mutant presenilin 1. Nature 383 , 710–713 (1996). Article CAS Google Scholar ...

Mild cognitive impairment is linked to blood vessel dysfunction in the brain's temporal lobes—the seat of memory—according to ...

The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners ...

Mild cognitive impairment is linked to blood vessel dysfunction in the brain's temporal lobes -- the seat of memory -- according to a new study. The findings, seen in people with and without signs of ...

Ever since Alois Alzheimer first described the neurological changes that characterize the disease that now bears his name, amyloid plaques have been a central focus of AD research. By the early ...

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...

The litany of failed trials of amyloid-targeting drugs for Alzheimer's disease has added another verse, as Roche concedes that its crenezumab candidate was unable to slow cognitive decline in ...

The drugs attack so-called amyloid plaques in the brain. But how can we reliably and cost effectively diagnose the presence of amyloid plaques in patients who show up at memory clinics with slight ...

Tafamidis not only improves survival but also mitigates cardiac structural changes and functional declines, underscoring its ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.